The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Self-citationTargeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
Poliseno, L., Salmena, L., Zhang, J., Carver, B., Haveman, W. J., & Pandolfi, P. P. (2010) · Nature · doi:10.1038/nature09144 · Cited by 2,323
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
The landscape of cancer genes and mutational processes in breast cancer
The Oslo Breast Cancer Consortium (OSBREAC), Stephens, P. J., Tarpey, P. S., Davies, H., Van Loo, P., Greenman, C., Wedge, D. C., Nik-Zainal, S., Martin, S., Varela, I., et al. (2012) · Nature · doi:10.1038/nature11017 · Cited by 1,698
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402824 · Cited by 1,176
Phosphorylation and Regulation of Raf by Akt (Protein Kinase B)
Zimmermann, S., & Moelling, K. (1999) · Science · doi:10.1126/science.286.5445.1741 · Cited by 1,078
Whole-genome analysis informs breast cancer response to aromatase inhibition
Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., Van Tine, B. A., Hoog, J., Goiffon, R. J., Goldstein, T. C., et al. (2012) · Nature · doi:10.1038/nature11143 · Cited by 1,023
Sawyers, C. L. (2008) · Nature · doi:10.1038/nature06913 · Cited by 983
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
The PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 878
Junttila, T. T., Akita, R. W., Parsons, K., Fields, C., Lewis Phillips, G. D., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 829
Expression of Cellular Oncogenes in Human Malignancies
Slamon, D. J., deKernion, J. B., Verma, I. M., & Cline, M. J. (1984) · Science · doi:10.1126/science.6538699 · Cited by 827
Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A., Schröder, C. P., Lub-de Hooge, M. N., & de Vries, E. G. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.12 · Cited by 805
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
Wan, X., Harkavy, B., Shen, N., Grohar, P., & Helman, L. J. (2007) · Oncogene · doi:10.1038/sj.onc.1209990 · Cited by 755
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645
Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D., Brandhuber, B. J., Gross, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578
Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., Molina, J. R., Hanson, L. J., Gore, L., Chow, L., Leong, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4956 · Cited by 570
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S.-M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.-M., & Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545
Serra, V, Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 528
Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
Graupera, M., Guillermet-Guibert, J., Foukas, L. C., Phng, L.-K., Cain, R. J., Salpekar, A., Pearce, W., Meek, S., Millan, J., Cutillas, P. R., et al. (2008) · Nature · doi:10.1038/nature06892 · Cited by 520
Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702507104 · Cited by 520
European cancer mortality predictions for the year 2013
Malvezzi, M., Bertuccio, P., Levi, F., La Vecchia, C., & Negri, E. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt010 · Cited by 514
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 509
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 463
Sugimoto, Y., Whitman, M., Cantley, L. C., & Erikson, R. L. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.7.2117 · Cited by 462
Janku, F., Wheler, J. J., Westin, S. N., Moulder, S. L., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido-Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 447
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 440
Predictors of Competing Mortality in Advanced Head and Neck Cancer
Mell, L. K., Dignam, J. J., Salama, J. K., Cohen, E. E. W., Polite, B. N., Dandekar, V., Bhate, A. D., Witt, M. E., Haraf, D. J., Mittal, B. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9288 · Cited by 433
She, Q.-B., Solit, D. B., Ye, Q., O’Reilly, K. E., Lobo, J., & Rosen, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 421
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
The role of mitogen-activated protein (MAP) kinase in breast cancer
Santen, R. J., Song, R. X., McPherson, R., Kumar, R., Adam, L., Jeng, M.-H., & Yue, W. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00189-3 · Cited by 406
She, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400
European cancer mortality predictions for the year 2012
Malvezzi, M., Bertuccio, P., Levi, F., La Vecchia, C., & Negri, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds024 · Cited by 386
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Friday, B. B., & Adjei, A. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4790 · Cited by 374
Strategies for optimizing combinations of molecularly targeted anticancer agents
Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 365
Self-citationLoi, S., Haibe-Kains, B., Majjaj, S., Lallemand, F., Durbecq, V., Larsimont, D., Gonzalez-Angulo, A. M., Pusztai, L., Symmans, W. F., Bardelli, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907011107 · Cited by 356
Self-citationSaal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355
Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 343
Giroux, S., Tremblay, M., Bernard, D., Cardin-Girard, J.-F., Aubry, S., Larouche, L., Rousseau, S., Huot, J., Landry, J., Jeannotte, L., et al. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80164-x · Cited by 341
Brachmann, S. M., Hofmann, I., Schnell, C., Fritsch, C., Wee, S., Lane, H., Wang, S., Garcia-Echeverria, C., & Maira, S.-M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905152106 · Cited by 303
Janku, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
Sparks, C. A., & Guertin, D. A. (2010) · Oncogene · doi:10.1038/onc.2010.139 · Cited by 299
Incidence of Breast Cancer in the United States: Current and Future Trends
Anderson, W. F., Katki, H. A., & Rosenberg, P. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr257 · Cited by 285
Kefford, R., Arkenau, H., Brown, M. P., Millward, M., Infante, J. R., Long, G. V., Ouellet, D., Curtis, M., Lebowitz, P. F., & Falchook, G. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8503 · Cited by 275
Wolff, A. C., Lazar, A. A., Bondarenko, I., Garin, A. M., Brincat, S., Chow, L., Sun, Y., Neskovic-Konstantinovic, Z., Guimaraes, R. C., Fumoleau, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3331 · Cited by 272
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1577 · Cited by 262
Future of Personalized Medicine in Oncology: A Systems Biology Approach
Gonzalez-Angulo, A. M., Hennessy, B. T. J., & Mills, G. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0777 · Cited by 261
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3033 · Cited by 258
Sos, M. L., Fischer, S., Ullrich, R., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 254
PI(3)King Apart PTEN's Role in Cancer
Zhang, S., & Yu, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2990 · Cited by 248
Creighton, C. J., Hilger, A. M., Murthy, S., Rae, J. M., Chinnaiyan, A. M., & El-Ashry, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4363 · Cited by 243
Hennessy, B. T., Lu, Y., Gonzalez-Angulo, A. M., Carey, M. S., Myhre, S., Ju, Z., Davies, M. A., Liu, W., Coombes, K., Meric-Bernstam, F., et al. (2010) · Clinical Proteomics · doi:10.1007/s12014-010-9055-y · Cited by 241
Tian, Q., Price, N. D., & Hood, L. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02498.x · Cited by 224
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Stemke-Hale, K., Sahin, A., Liu, S., Barrera, J. A., Burgues, O., Lluch, A. M., Chen, H., Hortobagyi, G. N., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1089 · Cited by 219
Marty, B., Maire, V., Gravier, E., Rigaill, G., Vincent-Salomon, A., Kappler, M., Lebigot, I., Djelti, F., Tourdès, A., Gestraud, P., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2204 · Cited by 216
Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211
Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2321 · Cited by 209
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
Janku, F., Lee, J. J., Tsimberidou, A. M., Hong, D. S., Naing, A., Falchook, G. S., Fu, S., Luthra, R., Garrido-Laguna, I., & Kurzrock, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022769 · Cited by 204
Weigelt, B., Warne, P. H., & Downward, J. (2011) · Oncogene · doi:10.1038/onc.2011.42 · Cited by 190
HAUSENLOY, D. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.04.011 · Cited by 188
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes
Pal, I., & Mandal, M. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.72 · Cited by 179
Srinivasan, R., Zabuawala, T., Huang, H., Zhang, J., Gulati, P., Fernandez, S., Karlo, J. C., Landreth, G. E., Leone, G., & Ostrowski, M. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008283 · Cited by 178
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Zhang, Y.-J., Duan, Y., & Zheng, X. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.008 · Cited by 173
Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis
Mittal, S., Subramanyam, D., Dey, D., Kumar, R. V., & Rangarajan, A. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-128 · Cited by 170
Chapuis, N., Tamburini, J., Green, A. S., Vignon, C., Bardet, V., Neyret, A., Pannetier, M., Willems, L., Park, S., Macone, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1102 · Cited by 164
Cotargeting survival signaling pathways in cancer
Grant, S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36898 · Cited by 164
Ihle, N. T., Paine-Murrieta, G. D., Berggren, M. I., Baker, A. F., Tate, W. R., Wipf, P., Abraham, R. T., Kirkpatrick, D. L., & Powis, G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0149 · Cited by 154
Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
Vilar, E., Pérez-García, J. M., & Tabernero, J. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0905 · Cited by 150
Azim, H. A., Michiels, S., Zagouri, F., Delaloge, S., Filipits, M., Namer, M., Neven, P., Symmans, W. F., Thompson, A. M., André, F., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds645 · Cited by 145
Self-citationCotargeting survival signaling pathways in cancer
Grant, S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36898e1 · Cited by 141
Balmanno, K., Chell, S. D., Gillings, A. S., Hayat, S., & Cook, S. J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24604 · Cited by 140
McDermott, U., & Settleman, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9054 · Cited by 131
Hassett, M. J., Silver, S. M., Hughes, M. E., Blayney, D. W., Edge, S. B., Herman, J. G., Hudis, C. A., Marcom, P. K., Pettinga, J., Share, D. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5740 · Cited by 130
Challenges translating breast cancer gene signatures into the clinic
Weigelt, B., Pusztai, L., Ashworth, A., & Reis-Filho, J. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.125 · Cited by 122
Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos, P. I., & Solit, D. B. (2011) · Science Signaling · doi:10.1126/scisignal.2001948 · Cited by 119
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
Bianchi, G., Loibl, S., Zamagni, C., Salvagni, S., Raab, G., Siena, S., Laferriere, N., Peña, C. E., Lathia, C. D., Bergamini, L., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832b2ea0 · Cited by 116
Santarpia, L., Qi, Y., Stemke‐Hale, K., Wang, B., Young, E. J., Booser, D. J., Holmes, F. A., O’Shaughnessy, J., Hellerstedt, B. A., Pippen, J., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2035-3 · Cited by 109
Burris, H. A., Rodon, J. A., Sharma, S., Herbst, R. S., Tabernero, J. M., Infante, J. R., Silva, A. M. E., Demanse, D., Hackl, W., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3005 · Cited by 109
INPP4B: the New Kid on the PI3K Block
Agoulnik, I. U., Hodgson, M. C., Bowden, W. A., & Ittmann, M. (2011) · Oncotarget · doi:10.18632/oncotarget.260 · Cited by 106
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
Weigelt, B., & Downward, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00109 · Cited by 102
Tanaka, H., Yoshida, M., Tanimura, H., Fujii, T., Sakata, K., Tachibana, Y., Ohwada, J., Ebiike, H., Kuramoto, S., Morita, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2882 · Cited by 102
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
Gonzalez-Angulo, A. M., & Blumenschein, G. R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.11.002 · Cited by 101
Rebbeck, T. R., DeMichele, A. M., Tran, T. V., Panossian, S., Bunin, G. R., Troxel, A. B., & Strom, B. L. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn247 · Cited by 95
Schwartz, G. K., Robertson, S., Shen, A., Wang, E., Pace, L., Dials, H. J., Mendelson, D. S., Shannon, P., & Gordon, M. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3513 · Cited by 95
ERK and Beyond: Insights from B-Raf and Raf-1 Conditional Knockouts
Galabova‐Kovacs, G., Kolbus, A., Matzen, D., Meiss, K., Piazzolla, D., Rubiolo, C., Steinitz, K. N., & Baccarini, M. (2006) · Cell Cycle · doi:10.4161/cc.5.14.2981 · Cited by 88
Polyák, K., & Filho, O. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.021 · Cited by 85
Boyault, S., Drouet, Y., Navarro, C., Bachelot, T., Lasset, C., Treilleux, I., Tabone, É., Puisieux, A., & Wang, Q. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1518-y · Cited by 85
Rheb Inhibits C-Raf Activity and B-Raf/C-Raf Heterodimerization
Karbowniczek, M., Robertson, G. P., & Henske, E. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605273200 · Cited by 83
Phase II trial of temsirolimus in patients with metastatic breast cancer
Fleming, G. F., Ma, C. X., Huo, D., Sattar, H. A., Tretiakova, M., Li, L., Hahn, O. M., Olopade, F. O., Nanda, R., Hoffman, P. C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1910-7 · Cited by 78
A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors
Creighton, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210245 · Cited by 73
Wagner, A. J., Bendell, J. C., Dolly, S. O., Morgan, J. A., Ware, J. A., Fredrickson, J. O., Mazina, K. E., Lauchle, J., Burris, H. A., & Bono, J. S. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3020 · Cited by 73
Quinlan, J., Gaydos, B. L., Maca, J., & Krams, M. (2010) · Clinical Trials · doi:10.1177/1740774510361542 · Cited by 70
Cosimo, S. D., Bendell, J. C., Cervantes, A. M. R., Roda, D., Prudkin, L., Stein, M. N., Leighton-Swayze, A., Song, Y., Ebbinghaus, S., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3008 · Cited by 67
Vasudevan, K. M., Burikhanov, R., Goswami, A., & Rangnekar, V. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1827 · Cited by 65
Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology
Glimelius, B. L. G., & Lahn, M. M. F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq622 · Cited by 64
Tolcher, A. W., Yap, T. A., Fearen, I., Taylor, A., Carpenter, C., Brunetto, A. T., Beeram, M., Papadopoulos, K. P., Yan, L., & Bono, J. S. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3503 · Cited by 64
Garon, E. B., Finn, R. S., Hosmer, W., Dering, J., Ginther, C., Adhami, S., Kamranpour, N., Pitts, S. L., Desai, A. J., Elashoff, D. A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0037 · Cited by 63
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
Meng, J., Peng, H., Dai, B., Guo, W., Wang, L., Ji, L., Minna, J. D., Chresta, C. M., Smith, P. D., Fang, B., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.21.9844 · Cited by 62
Juric, D., Rodon, J. A., Gonzalez-Angulo, A. M., Burris, H. A., Bendell, J. C., Berlin, J. D., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-ct-01 · Cited by 62
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines
Whyte, D. B., & Holbeck, S. L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.025 · Cited by 60
Bachelot, T., Bourgier, C., Cropet, C., Guastalla, J. P., Ferrero, J.-M., Falandry, C., Soulié, P., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-s1-6 · Cited by 59
Sánchez-Fructuoso, A. I., Ruiz, J. C., Pérez-Flores, I., Alamillo, C. G., Romero, N. C., & Arias, M. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.07.083 · Cited by 53
Braña, I., LoRusso, P. M., Baselga, J. M., Heath, E. I., Patnaik, A., Gendreau, S., Laird, A., & Papadopoulos, K. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3030 · Cited by 51
Wallin, J. J., Guan, J., Edgar, K. A., Zhou, W., Francis, R., Torres, A. C., Haverty, P. M., Eastham‐Anderson, J., Arena, S., Bardelli, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036402 · Cited by 50
Tan, D. S.-W., Dumez, H., Olmos, D., Sandhu, S. K., Hoeben, A., Stephens, A. W., Poondru, S., Gedrich, R. W., Kaye, S. B., & Schöffski, P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3006 · Cited by 50
Burris, H. A., Siu, L. L., Infante, J. R., Wheler, J. J., Kurkjian, C. D., Opalinska, J., Smith, D. A., Antal, J. M., Gauvin, J., Gonzalez, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3003 · Cited by 50
Zardavas, D., Fumagalli, D., & Loi, S. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328358a2b5 · Cited by 48
Self-citationShapiro, G. I., Kwak, E. L., Baselga, J. M., Rodon, J. A., Scheffold, C., Laird, A., Bedell, C., & Edelman, G. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3500 · Cited by 45
Shapiro, G. I., LoRusso, P. M., Kwak, E. L., Cleary, J. M., Musib, L. C., Jones, C. B., de Crespigny, A. J., Belvin, M. P., McKenzie, M., Gates, M. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3005 · Cited by 44
Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
Jokinen, E., Laurila, N., & Koivunen, J. P. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-612 · Cited by 42
LoRusso, P. M., Markman, B., Tabernero, J. M., Shazer, R. L., Nguyen, L. T., Heath, E. I., Patnaik, A., & Papadopoulos, K. P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3502 · Cited by 39
Juric, D., Rodon, J. A., Gonzalez-Angulo, A., Burris, H. A., Bendell, J. C., Berlin, J., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., et al. (2012) · Cancer Research · Cited by 39
Huynh, H. T. (2010) · Cancer · doi:10.1002/cncr.24863 · Cited by 38
Clermont, A. C., Cahill, M. T., Salti, H. I., Rook, S. L., Rask‐Madsen, C., Goddard, L., Wong, J. S., Bursell, D., Bursell, S. E., & Aiello, L. P. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-0071 · Cited by 37
Delord, J., Houédé, N., Awada, A. H., Taamma, A., Faivre, S. J., Besse‐Hammer, T., Italiano, A., Vignaud, C. M. D., Donica, M., & Raymond, É. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2504 · Cited by 36
Khan, K. H., Yan, L., Mezynski, J., Patnaik, A., Moreno, V., Papadopoulos, K. P., Garrett, C. R., Ong, M., Shannon, K. A., Morosky, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.e13599 · Cited by 36
Michelucci, A., Cristofano, C. D., Lami, A., Collecchi, P., Caligo, M. A., Decarli, N., Leopizzi, M., Aretini, P., Bertacca, G., Porta, R. P., et al. (2009) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31818e5fa4 · Cited by 35
Tolcher, A. W., Baird, R. D., Patnaik, A., Garcia, V. M., Papadopoulos, K. P., Garrett, C. R., Olmos, D., Shannon, K., Zazulina, V., Rubin, E. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3004 · Cited by 35
Yonemori, K., Tsuta, K., Shimizu, C., Hatanaka, Y., Hashizume, K., Ono, M., Kouno, T., Ando, M., Tamura, K., Katsumata, N., et al. (2008) · Medical Oncology · doi:10.1007/s12032-008-9127-2 · Cited by 31
Guénard, F., Labrie, Y., Ouellette, G., Beauparlant, C. J., Bessette, P., Chiquette, J., Laframboise, R., Lépine, J., Lespérance, B., Pichette, R., et al. (2007) · Familial Cancer · doi:10.1007/s10689-007-9151-y · Cited by 30
Chang, Q., Chen, E., & Hedley, D. W. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.20.9430 · Cited by 30
Bendell, J. C., Papadopoulos, K. P., Jones, S. F., Barrett, E., Guthrie, K., Kass, C. L., Litwiler, K. S., Napier, C., & Patnaik, A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-b243 · Cited by 30
Münster, P. N., van der Noll, R., Voest, E. E., Dees, E. C., Tan, A. R., Specht, J. M., Falchook, G. S., DAUD, A. I., Lolkema, M. P., Grilley‐Olson, J. E., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3018 · Cited by 28
Barbareschi, M., Cuorvo, L. V., Girlando, S., Bragantini, E., Eccher, C., Leonardi, E., Ferro, A., Caldara, A., Triolo, R., Cantaloni, C., et al. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1267-2 · Cited by 28
Malaguti, P., Vari, S., Cognetti, F., & Fabi, A. (2013) · PubMed · Cited by 27
Neoadjuvant therapy in early-stage breast cancer
Moreno‐Aspitia, A. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.013 · Cited by 25
Personalised medicine in oncology: questions for the next 20 years
Blay, J., Lacombe, D. A., Meunier, F., & Stupp, R. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70156-0 · Cited by 21
Millham, R., Houk, B. E., Borzillo, G. V., Tabernero, J. M., Bell‐McGuinn, K. M., Bendell, J. C., Molina, J. R., Kwak, E. L., & Shapiro, G. I. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-a167 · Cited by 20
Houédé, N., Faivre, S. J., Awada, A. H., Raymond, É., Italiano, A., Besse‐Hammer, T., Donica, M., Rejeb, N., Lüpfert, C., Ongarello, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3019 · Cited by 19
Münster, P. N., van der Noll, R., Voest, E. E., Specht, J. M., Werner, T. L., Dees, E. C., Tan, A., DAUD, A. I., Schellens, J. H. M., Lolkema, M. P., et al. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)33038-6 · Cited by 13
Gore, L., Lewis, K. A., Hoff, D. D. V., Weiss, G. J., Ramanathan, R., Adjei, A. A., Dy, G. K., Ma, W. W., Clendeninn, N. J., Leffingwell, D. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3007 · Cited by 11
Determining PTEN Functional Status by Network Component Deduced Transcription Factor Activities
Tran, L. M., Chang, C.-J., Plaisier, S. B., Wu, S., Dang, J. H. T., Mischel, P. S., Liao, J. C., Graeber, T. G., & Wu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031053 · Cited by 10
Kalinsky, K. M., Sparano, J., Kim, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.tps147 · Cited by 10
Leijen, S., Middleton, M. R., Tresca, P., Kraeber‐Bodéré, F., Dieras, V. C., Scheulen, M. E., Tessier, J. J. L., Xu, Z., Shochat, E., Walz, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3017 · Cited by 8
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L., Gunn, S. R., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2502 · Cited by 6
The most important news at ASCO 2009
DeVita, V. T. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.93 · Cited by 3
Hoeflich, K. P., Merchant, M. A., Otter, D. D., Chan, J., Chan, E. W., Orr, C., Friedman, L. S., Chan, I. T., Prescott, J., Berry, L., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-a250 · Cited by 1
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.012 · Cited by 612
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Han, B., He, X.-H., Liu, Y.-Q., He, G., Peng, C., & Li, J.-L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 402
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Metadata
- Authors
- Saini, K. S., Loi, S., de Azambuja, E., Metzger-Filho, O., Saini, M. L., Ignatiadis, M., Dancey, J. E., & Piccart-Gebhart, M. J.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 39
- Issue
- 8
- Pages
- 935-946
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2089605820
- Cited by
- 374
- References
- 160
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.